Alnylam Pharmaceuticals
Yahoo Finance • 2 days ago
Panic grips Ionis Pharmaceuticals investors amid bad news spree
A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua fai... Full story
Yahoo Finance • 4 days ago
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?
In recent days, Alnylam Pharmaceuticals has benefited from the late-stage failure of AstraZeneca and Ionis's competing ATTR-CM trial, alongside expanded AI and regional partnerships that deepen access to its RNAi therapies across new Europ... Full story
Yahoo Finance • 4 days ago
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca and Ionis Pharma reported a failure in a late-stage ATTR-CM trial, removing a key competing approach in transthyretin... Full story
Yahoo Finance • 4 days ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alnylam Pharmaceuticals stock has delivered an 81.9% gain over the... Full story
Yahoo Finance • 4 days ago
US Stock Market Today: S&P 500 Futures Edge Higher On Persistent Higher Yield Concerns
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The Morning Bull - US Market Morning Update Friday, Jul, 10 2026... Full story
Yahoo Finance • 5 days ago
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story
Yahoo Finance • 5 days ago
Strength in Chipmakers Boosts Stock Indexes
The S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.27%. September E-mini S&P futures (ESU26) are up +0.49%, and September E-mini... Full story
Yahoo Finance • 5 days ago
Stocks Climb on Strength in Chipmakers
The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%. September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini... Full story
Yahoo Finance • 5 days ago
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
Quick Read Cramer calls IBB the hottest group in the market, up 51% over the past year, with LLY completing four acquisitions in Q1 2026 alone. ALNY fell 21% YTD despite 187% revenue growth, the kind of dislocation Cramer says attracts st... Full story
Yahoo Finance • 5 days ago
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story
Yahoo Finance • 19 days ago
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation... Full story
Yahoo Finance • 22 days ago
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals, In... Full story
Yahoo Finance • last month
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
Key Points Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better. Alnylam set new 2030 goals targeting 25% annual revenue growth and a 30% non-GAAP operating margin, with management saying the plan is meant to c... Full story
Yahoo Finance • last month
Stocks Rebound on Strength in Banks and Managed Healthcare
The S&P 500 Index ($SPX) (SPY) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.73%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.53%. June E-mini S&P futures (ESM26) rose +0.36%, and June... Full story
Yahoo Finance • last month
Stocks Mixed as Tech Weakness Weighs
The S&P 500 Index ($SPX) (SPY) today is up +0.02%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.90%. June E-mini S&P futures (ESM26) are up +0.02%, and June E-mini Nasdaq f... Full story
Yahoo Finance • last month
Weakness in Technology Stocks Pressures Stock Indexes
The S&P 500 Index ($SPX) (SPY) today is down -0.16%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.41%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.23%. June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Nasd... Full story
Yahoo Finance • last month
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced partnership with Inceptive Nucleics, Inc., an artificial intelligence-driven biotechnology company, in a deal valued at up to approximately $2 billion. The partnership combines A... Full story
Yahoo Finance • last month
Alnylam to collaborate with Inceptive to use AI for RNAi therapy development
[Artificial Intelligence in Healthcare, AI Health, digital healthcare provider, telemedicine, medical technology] Just_Super * Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) has signed a deal potentially worth up... Full story
Yahoo Finance • last month
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Jakob UszkoreitInceptive LogoAlnylam OfficeInceptive OfficeAlnylam B-Roll − Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam’s RNAi platform and 20+ years of proprietary data with Incepti... Full story
Yahoo Finance • 2 months ago
JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story